Disintegrin Metalloprotease and Endothelial Dysfunction in Sepsis
脓毒症中的解整合素金属蛋白酶和内皮功能障碍
基本信息
- 批准号:9380597
- 负责人:
- 金额:$ 28.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-01 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AlbuminsAlpha CellAnimal OrganAnimalsAttentionBiologicalBiological MarkersBloodBlood CirculationBlood Coagulation DisordersBlood VesselsCD44 geneCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeCharacteristicsCleaved cellClinical TrialsCollaborationsCritical IllnessCytoplasmic TailDataDevelopmentDiagnosisDiseaseDisintegrinsEdemaEndotheliumEnzymesExperimental ModelsExposure toExtravasationFamilyFamily memberFunctional disorderFundingGlycocalyxGlycoproteinsGlycosaminoglycansGrantHemorrhageHost DefenseHumanHyaluronanImmune responseInfectionInflammationInflammatoryInjuryInterventionInvestigationInvestigational TherapiesLeukocytesLifeLinkLungMediatingMedical emergencyMembraneMetalloproteasesMicroRNAsMicrovascular DysfunctionMolecularMolecular AnalysisMolecular StructureMolecular TargetMusOperative Surgical ProceduresOrganOrgan ProcurementsPathogenesisPathway interactionsPeptide HydrolasesPermeabilityPharmaceutical PreparationsPhysiologicalPlasmaPlayPreventionPreventiveProcessPropertyProteoglycanReactionReportingResearch PersonnelRoleSepsisSeriesSex CharacteristicsSignal TransductionSnake VenomsStressStructureSurfaceSymptomsTechniquesTestingTherapeuticTissuesTraumaUp-RegulationVascular EndotheliumWorkage differenceclinically relevantcomparativedesignendothelial dysfunctionin vivoinhibitor/antagonistinnovationinsightmicroscopic imagingmigrationmortalityneutrophilnew therapeutic targetnovelnovel therapeuticsoutcome forecastpreventrespiratory distress syndromeresponsesepticsyndecantargeted treatmenttherapeutic evaluationvascular inflammation
项目摘要
PROJECT SUMMARY/ABSTRACT
Snakebite victims often present with sepsis-like symptoms, such as edema and respiratory distress syndrome.
Analyses of snake venoms have identified a family of proteases characteristic of disintegrin metalloproteases
(ADAMs) with the capability to cleave transmembrane molecules. Our previous work supported by this grant
has focused on a unique member of this family, ADAM15, with respect to its molecular structure and function in
regulating endothelial barrier property. We reported ADAM15 upregulation in the lungs and vascular tissues
during inflammation, where it increases endothelial permeability and promotes leukocyte migration via Src-
dependent signaling transduced by its cytoplasmic domain. In this renewal application, we plan to bring our
investigation on ADAM15 to the next level by examining its novel molecular targets with high translational
values and therapeutic potential. The studies will focus on endothelial glycocalyx, a barrier protective structure
composed of glycosaminoglycan chains linked to transmembrane proteoglycans and glycoproteins, which are
shed into the circulation following injury or major surgery. The central pathway to be tested is that during septic
injury, ADAM15 cleaves these transmembrane molecules leading to glycocalyx degradation. The exposure of
endothelium to circulating cells and agents, along with shedding products acting as hyperpermeability factors,
promotes plasma leakage and leukocyte diapedesis. Three specific aims are proposed: 1) to characterize
ADAM-induced glycocalyx injury during sepsis; 2) to elucidate the molecular mechanisms by which ADAM
causes glycocalyx degradation; and 3) to test the therapeutic potential of targeting the ADAM-glycocalyx
pathway for treating sepsis. We will employ complementary approaches that integrate physiological responses
and molecular reactions at organ, tissue, and cell levels. Innovative experimental models and therapies will be
tested. A unique design is the characterization of lung pathophysiology under clinically relevant conditions,
taking advantage of the available intact viable human organs provided by a federally certified organ
procurement organization. Data derived from the proposed work will provide new mechanistic insights into the
molecular pathogenesis of sepsis. The study will also assist in the identification and development of novel
therapeutic targets for treating vascular inflammatory injury associated with infection, trauma or major surgery.
项目总结/摘要
蛇咬伤的受害者经常出现败血症样症状,如水肿和呼吸窘迫综合征。
对蛇毒的分析已经鉴定了一个蛋白酶家族,其特征是去整合素金属蛋白酶
(亚当斯)具有切割跨膜分子的能力。我们以前的工作得到了这笔赠款的支持
一直专注于这个家族的一个独特成员,ADAM 15,就其分子结构和功能而言,
调节内皮屏障特性。我们报道了肺和血管组织中的ADAM 15上调,
在炎症过程中,它增加内皮通透性,并通过Src-
依赖于由其胞质结构域转导的信号传导。在这次更新申请中,我们计划将我们的
通过检测具有高翻译活性的新型分子靶点,将ADAM 15的研究推向新的水平。
价值和治疗潜力。这些研究将集中在内皮糖萼,一种屏障保护结构
由与跨膜蛋白聚糖和糖蛋白连接的糖胺聚糖链组成,
在受伤或大手术后流入血液循环。要测试的中央通路是在脓毒症期间
损伤时,ADAM 15切割这些跨膜分子,导致糖萼降解。的曝光
内皮细胞与循环细胞和试剂,沿着作为高渗透性因子的脱落产物,
促进血浆渗漏和白细胞渗出。提出了三个具体目标:1)表征
脓毒症期间ADAM诱导的糖萼损伤; 2)阐明ADAM诱导糖萼损伤的分子机制
导致糖萼降解;和3)测试靶向ADAM-糖萼的治疗潜力
治疗败血症的途径。我们将采用互补的方法,整合生理反应
以及器官、组织和细胞水平的分子反应。创新的实验模型和疗法将成为
测试.独特的设计是在临床相关条件下表征肺病理生理学,
利用联邦认证的器官提供的可用的完整活体人体器官
采购组织。从拟议的工作中获得的数据将为研究
脓毒症的分子发病机制。这项研究也将有助于识别和发展的小说
用于治疗与感染、创伤或大手术相关的血管炎性损伤的治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah Y Yuan其他文献
Sarah Y Yuan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah Y Yuan', 18)}}的其他基金
Training in Research on Vascular Inflammation and Injury
血管炎症和损伤研究培训
- 批准号:
10332781 - 财政年份:2022
- 资助金额:
$ 28.41万 - 项目类别:
Training in Research on Vascular Inflammation and Injury
血管炎症和损伤研究培训
- 批准号:
10531933 - 财政年份:2022
- 资助金额:
$ 28.41万 - 项目类别:
Disintegrin Metalloprotease and Endothelial Permeability
解整合素金属蛋白酶和内皮通透性
- 批准号:
8655168 - 财政年份:2011
- 资助金额:
$ 28.41万 - 项目类别:
Disintegrin Metalloprotease and Endothelial Permeability
解整合素金属蛋白酶和内皮通透性
- 批准号:
8402011 - 财政年份:2011
- 资助金额:
$ 28.41万 - 项目类别:
Disintegrin Metalloprotease and Endothelial Dysfunction in Sepsis
脓毒症中的解整合素金属蛋白酶和内皮功能障碍
- 批准号:
9908099 - 财政年份:2011
- 资助金额:
$ 28.41万 - 项目类别:
Disintegrin Metalloprotease and Endothelial Permeability
解整合素金属蛋白酶和内皮通透性
- 批准号:
8458134 - 财政年份:2011
- 资助金额:
$ 28.41万 - 项目类别:
相似海外基金
The Role of Arginine Transport on Pancreatic Alpha Cell Proliferation and Function
精氨酸转运对胰腺α细胞增殖和功能的作用
- 批准号:
10678248 - 财政年份:2023
- 资助金额:
$ 28.41万 - 项目类别:
Alpha cell-derived Extracellular Vesicles and Maternal Insulin Production
α细胞来源的细胞外囊泡和母体胰岛素的产生
- 批准号:
10681939 - 财政年份:2023
- 资助金额:
$ 28.41万 - 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
- 批准号:
10427574 - 财政年份:2022
- 资助金额:
$ 28.41万 - 项目类别:
Regulation of alpha-cell glucagon secretion by mitochondrial anaplerosis-cataplerosis
线粒体回补-回补对α细胞胰高血糖素分泌的调节
- 批准号:
10607392 - 财政年份:2022
- 资助金额:
$ 28.41万 - 项目类别:
Arginine regulation of alpha cell proliferation and function
精氨酸调节α细胞增殖和功能
- 批准号:
10609909 - 财政年份:2022
- 资助金额:
$ 28.41万 - 项目类别:
Targeting alpha-cell GPCRs to stimulate glucagon and counter hypoglycemia
靶向 α 细胞 GPCR 刺激胰高血糖素并对抗低血糖
- 批准号:
10675646 - 财政年份:2022
- 资助金额:
$ 28.41万 - 项目类别:
Elucidating alpha cell defects in human type 1 diabetes using precision cut pancreas slice-on-a-chip coupled with high spatio-temporal microscopy
使用精密切割的胰腺切片结合高时空显微镜阐明人类 1 型糖尿病的 α 细胞缺陷
- 批准号:
457552 - 财政年份:2021
- 资助金额:
$ 28.41万 - 项目类别:
Studentship Programs
Defining alpha-cell proglucagon processing for type 2 diabetes treatment
定义 2 型糖尿病治疗的 α 细胞胰高血糖素原加工过程
- 批准号:
10331361 - 财政年份:2020
- 资助金额:
$ 28.41万 - 项目类别:
In vivo systems to discover mechanisms regulating human islet alpha cell function
体内系统发现调节人类胰岛α细胞功能的机制
- 批准号:
10623306 - 财政年份:2020
- 资助金额:
$ 28.41万 - 项目类别:
Deciphering alpha-cell heterogeneity using a novel reporter mouse
使用新型报告小鼠解读α细胞异质性
- 批准号:
20K08895 - 财政年份:2020
- 资助金额:
$ 28.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




